Life Science Compliance Update

July

2018

When “Free” Really Isn’t Free – A Look at the Abiomed Case

Written by , Posted in Uncategorized

Robert N. Wilkey, Esq.

In March, the United State Department of Justice (DOJ) and U.S. Attorney’s Office for the District of Massachusetts announced a $3.1 million-dollar settlement with Abiomed to resolve allegations that the company was actively using illicit marketing tactics with physicians to increase sales in a manner that violated the AKS and FCA.  Such settlement highlights that there is no such as a free lunch.


   or   

  • Return to July 2018 LSC Update Table of Contents
  • Copy abstract URL
  • Order Reprints
  • Topic tags:

    Menu Title